fbpx

News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.
nivolumab opdivo

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial

In the randomized, phase II (part 1) ATTRACTION-4 trial, nivolumab combined with chemotherapy [S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (CapeOX)] was evaluated in patients with chemonaïve, unresectable advanced or recurrent gastric/gastroesophageal junction cancer. Nivolumab plus SOX/CapeOX was well tolerated and demonstrated encouraging efficacy in this population.

Read Source
DonateMore InfoDonateMore Info
We cannot gather at a gala event this year, but a pandemic cannot stop us from joining together to ensure that the search to find a cure for gastric (stomach) cancer continues.

Join with us to fuel the next wave of progress.

Every contribution moves us closer to a cure.
Please join with us to fuel the next wave of progress. Together, we will defeat stomach cancer.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.
X